Mitral valve repair: oral anticoagulants limit the risk of bleeding

Antithrombosis after mitral repair: resolving clinical uncertainty

Mitral regurgitation (MR) represents one of the most prevalent valvular heart diseases worldwide, frequently requiring surgical or transcatheter intervention. While mitral valve repair (MVR) significantly improves prognosis, it exposes patients to a critical thromboembolic risk, particularly during the first postoperative month where the incidence can reach 2.5% despite standard treatments. However, postoperative antithrombotic management remains a major point of friction between international guidelines: while the ACC/AHA recommends vitamin K antagonists (VKA) for three months, the ESC/EACTS favors an individualized approach, leaving a grey area regarding the optimal strategy.

This systematic review with network meta-analysis, integrating data from 12 clinical studies for a total of 20,644 participants, was designed to provide an evidence-based response. The objective is to compare the efficacy and safety of different antithrombotic options, including direct oral anticoagulants (DOACs), VKAs, and single or dual antiplatelet therapies (SAPT/DAPT). The study tests the hypothesis that a specific anticoagulant strategy could reduce thromboembolic events without compromising bleeding safety, thus providing a solid foundation for standardizing currently disparate post-MVR practices.

Methodology of the systematic review and meta-analysis

This study is a systematic review with network meta-analysis, conducted according to PRISMA guidelines and the Cochrane Handbook. The authors searched five databases (PubMed, Scopus, Ovid, Cochrane, and Web of Science) up to June 2024 to identify studies evaluating antithrombotic strategies after mitral valve repair (MVR).

The population and selection protocol include:

• Final sample: 12 cohort studies published between 2008 and 2022, selected from 121 articles after independent double screening.
• Population: A total of 20,644 adult patients who underwent surgical (SMVR) or percutaneous (TMVR) repair.
• Compared groups: Analyzed treatments included aspirin or single antiplatelet therapy (SAPT), dual antiplatelet therapy (DAPT), vitamin K antagonists (VKA), direct oral anticoagulants (OAC), and the absence of antiplatelet treatment.

The primary endpoints were the occurrence of thromboembolic events and bleeding within six months postoperatively. Secondary endpoints included strokes, transient ischemic attacks (TIA), and short-term mortality. The quality of the studies was assessed using the Newcastle-Ottawa Scale (NOS), and statistical analyses, including heterogeneity and publication bias, were performed using R software.

Analysis of Hemorrhagic and Thromboembolic Risks

The synthesis of data from this meta-analysis, involving a total cohort of 20,644 patients followed between 2008 and 2022, reveals significant disparities according to the antithrombotic strategies adopted after mitral valve repair (MVR).

The most significant result concerns the safety of use of oral anticoagulants (OAC). Compared to single antiplatelet therapy (SAPT), the use of OAC is associated with a major reduction in bleeding risk:

• Relative Risk (RR): 0.31
• 95% Confidence Interval (CI): [0.11–0.87]
• Significance: P < 0.05

This superiority of OACs in terms of safety is accompanied by moderate heterogeneity in the included studies.

Comparative Effectiveness on Ischemic Events

Unlike the results on bleeding, the analysis shows no statistically significant superiority of one molecule over another regarding the prevention of thromboembolic (TE) events at 6 months. Direct comparisons between single antiplatelet therapy (SAPT) and vitamin K antagonists (VKA) revealed no notable difference for stroke or transient ischemic attacks (TIA).

Mortality and Procedural Success

Six-month mortality rates are overall comparable between the SAPT and VKA groups. However, the authors report significant heterogeneity, with one specific study signaling higher mortality under SAPT. Qualitatively, data regarding transcatheter mitral valve repair (TMVR) confirm high procedural success rates, although bleeding complications remain the primary point of vigilance depending on the chosen intervention.

In summary, while VKAs or the combination of OAC + SAPT appear clinically oriented towards a reduction in thromboembolic events, only OACs demonstrate robust statistical superiority in reducing immediate post-operative bleeding complications.

Clinical data interpretation

The main finding of this systematic review lies in the unexpected safety profile of oral anticoagulants (OACs). Contrary to popular belief, the analysis shows that OACs significantly reduce the risk of bleeding compared to single antiplatelet therapy (SAPT), with a relative risk of 0.31. Regarding thrombotic efficacy, the compiled data indicate no statistically significant superiority of one strategy over the other concerning stroke, transient ischemic attacks, or mortality at six months. This suggests that intensifying OAC treatment does not compromise patient safety in the short term.

Limits and perspective

The strength of this analysis lies in the diversity of the included cohorts, but it faces notable heterogeneity, particularly regarding mortality data. The absence of randomised controlled trials (RCTs) constitutes the major limitation: as the included studies are observational, a selection bias related to institutional preferences or patient risk profiles (such as the presence of atrial fibrillation or ventricular remodelling) cannot be excluded. This reality echoes the discrepancies between the ACC/AHA recommendations, which favour warfarin for three months, and those of the ESC/EACTS, which are more cautious regarding the choice of treatment.

Implications for practice

For the practitioner, these results confirm that the choice of antithrombotic after mitral repair remains a precision decision. In the absence of clear superiority of a standardized protocol regarding embolic events, the benefit-risk balance must be evaluated on a case-by-case basis. The observed reduction in bleeding risk under OACs could encourage their use, but caution remains necessary until large-scale RCTs validate these observational data.

Summary of results

This meta-analysis, including 12 studies and 20,644 patients, shows that oral anticoagulants (OAC) significantly reduce the bleeding risk compared to single antiplatelet therapy (SAPT) (RR = 0.31, 95% CI: 0.11–0.87). No statistically significant difference was observed between strategies regarding thromboembolic events, stroke, TIA, or mortality at 6 months.

In concrete terms, for the practitioner:

• Prioritize oral anticoagulants: To reduce post-mitral repair hemorrhagic complications, OACs prove superior to simple antiplatelet agents without compromising embolic safety.
• Individualize according to risk: In the absence of strict consensus between the ACC/AHA (preference for Warfarin for 3 months) and the ESC/EACTS, adapt the prescription to the patient's specific risk profile and the technique (surgical or percutaneous).
• High-risk patients: The combination of OAC + SAPT or the use of VKAs may be considered to strengthen thromboembolic protection, although the benefit in reducing stroke has not yet been formally demonstrated by these data.

Technical lexicon of the study

Mitral regurgitation (MR): Valvular heart disease characterized by abnormal blood reflux, classified as primary (pathological alterations of the valve) or secondary (left ventricular modifications or atrial dilation).

TMVR / PMVR (Transcatheter Mitral Valve Repair): Percutaneous mitral valve repair technique (catheterization), preferred for patients at high surgical risk or considered inoperable.

SAPT (Single Antiplatelet Therapy): Single antiplatelet therapy protocol using a single agent (typically aspirin or clopidogrel), compared here to anticoagulation regimens.

VKA (Vitamin K Antagonists): Vitamin K antagonists (e.g. Warfarin), a class of oral anticoagulants evaluated for the prevention of post-operative thromboembolic complications.

Thromboembolic (TE) events: Complications including strokes and transient ischemic attacks (TIA), the incidence of which was measured at 6 months in this meta-analysis.

Newcastle-Ottawa Scale (NOS): Methodological quality assessment tool used in this review to analyze non-randomized cohort studies according to three domains: selection, comparability, and exposure.

Information intended for healthcare professionals. This content may contain errors or truncated summaries. We recommend always verifying with the original source article. Delynov disclaims all responsibility for the use of this information. This document is not intended for patients or the general public.